Bright Minds Biosciences' CEO, Ian McDonald, shares update on the company's multiple clinical trials.
Similar Posts
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Breaking News: MindMed launches LSD Microdosing Trial Treating ADHD (Plus MNMD Stock Discussion)
MindMed (Nasdaq:MNMD, NEO:MMED) has launched recruitment for their phase 2a clinical trial, testing using LSD microdoses to treat Adult ADHD!
MindMed’s stock has been down a lot recently, which has people asking “should I sell MindMed”, or “Is MindMed stock a good investment?”, or “why is MindMed stock down?”.
A lot of this drop has to do with a lack of news, not bad news. Now, at long last we finally have some good news! I have been looking forward to this trial starting for over a year now!
This LSD microdosing study is part of Project Flow, MindMed’s LSD microdosing division.
Microdosing LSD, anecdotally, has been shown to: increase focus; decrease anxiety; increase creativity; and improve mood. As improving focus and decreasing anxiety are two issues individuals with ADHD often need help with, it is possible that this may be a better medication than stimulants like Adderall.
The 52 person, placebo controlled study will give 20 micrograms of LSD to Adult ADHD sufferers twice a week for 6 weeks. Six weeks after treatment, the patients symptoms will be compared to where they were before the trial, and compared against the placebo group.
If they do show significant improvement, it will be the first scientific evidence that LSD microdoses can help treat adult ADHD.
Not only would this help tens of millions of people, it would also be lucrative for MindMed, as in the USA alone, the ADHD treatment market is valued at $12.9 billion annually.
Is LSD microdosing good for you? Can LSD Microdosing improve your mental health and Creativity? MindMed aims to find out!
References:
Press Release
https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html
MindMed Investor’s Deck
https://mindmed.co/wp-content/uploads/2021/12/MindMed-Presentation-December-2021.pdf
New CEO
https://www.newswire.ca/news-releases/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-879570624.html
Microdosing study 1
https://pubmed.ncbi.nlm.nih.gov/34795334/
Microdosing study 2
https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Microdosing #ADHD
MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
Psilocybin Trial Treating Depression CRUSHES It [Are We At A Turning Point?]
Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study’s primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.
And again, every secondary research objective heavily FAVORED psilocybin.
This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)
Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psilocybin #shroomboom
HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. The Effects of Treating Depression with Psilocybin
2. Taking Psychedelics in a Ritual Setting
3. Microdosing study
After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
Timestamps:
0:00 – Intro
1:24 – Effects of Treating Depression with Psilocybin
4:03 – Effects of Taking Psychedelics in A Ritual Setting
7:23 – Exploring the relationship between microdosing, personality & emotional insight
9:36 – Americans May be able to invest in Horizon’s ETF
11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
12:57 – Massachusetts Approves Psychedelics Decimalization
General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psychedelics #shroomboom
The Revolution in Mental Health Care: Psychedelics | PSILERA
In today’s episode, we speak with the leaders of Psilera…